logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo merck_oncology

ESMO 2017 : Combination therapy with abemaciclib and endocrine therapy improves the outcome in endocrine-sensitive advanced breast cancer

18-months interim analysis from the MONARCH 3 study helps also to identify the subgroup of patients that have good outcomes only with endocrine therapy.